<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Frank, MD, FACEP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allan B Wolfson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2590412574">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Procedural sedation and analgesia (PSA) reduces the patient’s discomfort, apprehension, and potentially unpleasant memories associated with procedures. Selecting a medication for procedural sedation in adults, including discharge criteria after the sedation is complete, will be reviewed here. Well-trained clinicians experienced in performing PSA who are monitoring patients appropriately and who are prepared to manage potential complications should choose the clinically appropriate sedative they are most comfortable administering.
        </p>
        <p>
         Preparation to perform a procedural sedation in adults, including monitoring and anticipating and managing complications, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/264.html" rel="external">
          "Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4193468610">
         <span class="h1">
          TOPIC SCOPE
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic provides guidance for procedural sedation in adult patients performed in the emergency department and other settings where the sedation is being performed by the proceduralist or a non-anesthesia clinician (eg, intensive care unit, procedural suite).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Procedural sedation in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Procedure sedation performed by endoscopists is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2567.html" rel="external">
          "Gastrointestinal endoscopy in adults: Procedural sedation administered by endoscopists"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2599.html" rel="external">
          "Adverse events related to procedural sedation for gastrointestinal endoscopy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitored anesthesia care (MAC) by an anesthesia clinician is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H918452081">
         <span class="h1">
          CHOOSING A MEDICATION
         </span>
        </p>
        <p class="headingAnchor" id="H3175829286">
         <span class="h2">
          Preferred medications in healthy patients: Propofol or etomidate
         </span>
         <span class="headingEndMark">
          —
         </span>
         In relatively healthy and hemodynamically stable patients, we suggest performing procedural sedation and analgesia (PSA) with either
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         , which are ultra-short-acting sedatives. Both medications are safe and effective, and both possess similar times to onset and recovery  (
         <a class="graphic graphic_table graphicRef52744" href="/z/d/graphic/52744.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. Propofol may result in a higher procedural success rate since it does not cause myoclonus, which can interfere with procedures [
         <a href="#rid1">
          1,3
         </a>
         ]. However, propofol may cause hypotension in patients with critical illnesses or decreased cardiac function since it is vasodilatory and a cardiac depressant. Respiratory depression occurs at comparable rates during PSA with either medication, but this rarely causes patient harm.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is preferable in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Musculoskeletal procedures –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         can cause myoclonus, which appears to reduce the rate of procedural success [
         <a href="#rid1">
          1,4-6
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with critical illnesses –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         causes dose-dependent adrenal suppression, which is unlikely to be important in otherwise healthy patients but may be harmful in patients with critical illnesses (eg, sepsis, multiple trauma)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         is preferable in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in whom hypotension is a particular concern, since it provides greater hemodynamic stability compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (see
         <a class="local">
          'Patients at risk for hypotension'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Several trials have compared
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         for PSA. A meta-analysis comparing PSA with etomidate versus propofol for electrical cardioversion (nine trials, 430 patients) found etomidate was less likely to cause hypoxia (10 versus 22 percent; RR 0.50, 95% CI 0.32-0.77) and hypotension (RR 0.11, 95% CI 0.02-0.74) and more likely to cause myoclonus (35 versus 3 percent; RR 8.89, 95% CI 4.59-17.23) and post-procedural nausea and vomiting (RR 5.13, 95% CI 1.72-15.3) [
         <a href="#rid7">
          7
         </a>
         ]. There was no difference in the use of positive-pressure ventilation for hypoxia and no reported use of inotropes for hypotension. A trial of 214 emergency department patients undergoing various painful procedures (musculoskeletal and others) also found that myoclonus was more frequent with etomidate (20 versus less than 2 percent with propofol), likely accounting for the lower rate of procedural success in the etomidate group (89 versus 97 percent) [
         <a href="#rid1">
          1
         </a>
         ]. There were no clinically significant complications (eg, prolonged hypoxia), and recovery after sedation was similar in the propofol and etomidate groups. Other studies of ocular and gastrointestinal procedures have shown similar quality of sedation and completion rates [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         There is insufficient evidence that "ketofol" (ie,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         mixed in 1:1 ratio) improves clinically significant outcomes or reduces important complications as compared with propofol alone, although it is a safe and effective combination for PSA. (See
         <a class="local">
          'Premixed with propofol (ketofol)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2210761140">
         <span class="h3">
          When ultra-short-acting agents are unavailable or a longer duration of PSA is required
         </span>
         <span class="headingEndMark">
          —
         </span>
         In settings where
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         are unavailable or a longer duration of PSA is required (eg, gastrointestinal endoscopy), a combination of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         plus
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         is commonly used. Although midazolam alone has not been shown to cause significant respiratory depression, the combination of midazolam and fentanyl can cause hypoxia and apnea and increases the need for airway intervention and medication reversal compared with PSA using ultra-short-acting agents (eg, propofol, etomidate) [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2567.html" rel="external">
          "Gastrointestinal endoscopy in adults: Procedural sedation administered by endoscopists", section on 'Sedatives and analgesics'
         </a>
         and
         <a class="local">
          'Coadministration of midazolam and fentanyl'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is also a reasonable option when a longer duration of PSA is required. (See
         <a class="local">
          'Ketamine'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4218908298">
         <span class="h2">
          Medication choice and dosing when increased risk of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some circumstances, the benefits of completing a procedure outweigh the anticipated risks of complications of PSA. Suggestions for medication selection in several common scenarios are provided below, and the doses and duration of effect and common adverse effects are presented in the table  (
         <a class="graphic graphic_table graphicRef52744" href="/z/d/graphic/52744.html" rel="external">
          table 1
         </a>
         ). Relative contraindications to PSA and considerations in patients with obesity or during pregnancy are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/264.html" rel="external">
          "Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'General considerations and precautions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/264.html" rel="external">
          "Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'Pregnancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/264.html" rel="external">
          "Procedural sedation in adults in the emergency department: General considerations, preparation, monitoring, and mitigating complications", section on 'Obesity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2591335976">
         <span class="h3">
          Patients at risk for hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients at risk of hypotension due to recent illness, dehydration, cardiac disease, or some other condition, we suggest using either
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA since either agent is expected to maintain hemodynamic stability. In contrast,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         has a greater hypotensive effect [
         <a href="#rid1">
          1
         </a>
         ]. Propofol-induced hypotension is generally mild and transient, but this difference may be of importance in patients with hypovolemia or hypotension who require emergency PSA [
         <a href="#rid12">
          12-14
         </a>
         ]. (See
         <a class="local">
          'Etomidate'
         </a>
         below and
         <a class="local">
          'Ketamine sedation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H625587474">
         <span class="h3">
          Patients at risk for airway or respiratory complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who may have a potentially difficult airway or compromised respiratory function, we suggest using
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA. Ketamine allows the patient to maintain protective airway reflexes and does not cause respiratory depression.
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is an alternative option since it generally preserves muscle tone and respiratory effort. (See
         <a class="local">
          'Ketamine sedation'
         </a>
         below and
         <a class="local">
          'Dexmedetomidine'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1024756432">
         <span class="h3">
          Patients with obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of medication for PSA is not affected by obesity, but dosing needs to be adjusted. Adjustments in the dosing of medications used for PSA should generally be based on ideal, adjusted, or lean body weight (not actual body weight [ABW]) to avoid oversedation and are described below. General principles regarding dosing of PSA medications in obesity are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14932.html" rel="external">
          "Anesthesia for the patient with obesity", section on 'Dosing anesthetic drugs'
         </a>
         .)
        </p>
        <p>
         Calculators for ideal body weight (IBW) and adjusted body weight (AdjBW) (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ), lean body weight in females and males (
         <a class="calc calc_professional" href="/z/d/html/13408.html" rel="external">
          calculator 2
         </a>
         and
         <a class="calc calc_professional" href="/z/d/html/13407.html" rel="external">
          calculator 3
         </a>
         ), and a table with IBW and approximate lean body weight  (
         <a class="graphic graphic_table graphicRef66098" href="/z/d/graphic/66098.html" rel="external">
          table 2
         </a>
         ) are provided.
        </p>
        <p>
         Dosing in patients with obesity is discussed in the section on each medication below.
        </p>
        <p class="headingAnchor" id="H3364313530">
         <span class="h3">
          Older adult patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Older adult patients are at increased risk of complications during PSA [
         <a href="#rid15">
          15-17
         </a>
         ]. As a result, sedatives administered to older patients for PSA, regardless of the agent, should be given at a lower starting dose, using a slower rate of administration, and repeating dosing at less frequent intervals. Dosing for specific medications is provided in the sections on individual medications below. (See
         <a class="local">
          'Medications'
         </a>
         below.)
        </p>
        <p>
         In older adult patients without major comorbidities or hemodynamic instability, it may be best to perform PSA using an ultra-short-acting sedative such as
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (initial bolus of no more than 0.5 mg/kg). Procedures in older adult patients with major comorbidities are probably best performed in the operating room if the anesthesiologist and proceduralist are available and any associated delay would not be harmful.
        </p>
        <p class="headingAnchor" id="H1388605651">
         <span class="h3">
          Patients with major medical conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with major comorbid medical conditions are at increased risk for adverse events with PSA. These conditions include heart failure, valvular (eg, aortic) stenosis, chronic obstructive pulmonary disease, pulmonary hypertension, and neuromuscular diseases and correlate with an American Society of Anesthesiologists (ASA) physical status classification of class III or greater  (
         <a class="graphic graphic_table graphicRef87504" href="/z/d/graphic/87504.html" rel="external">
          table 3
         </a>
         ). Similar to older patients, regardless of the sedative chosen for PSA, we suggest using a lower starting dose, slower rates of administration, and repeat dosing at less frequent intervals.
        </p>
        <p>
         Dosing in patients with hepatic or renal insufficiency is discussed in the section on each medication below. A lower starting dose is recommended for most agents except for
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         [
         <a href="#rid18">
          18-21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3925664643">
         <span class="h1">
          MEDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H873575989">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Procedural sedation and analgesia (PSA) typically involves the intravenous (IV) administration of sedative or dissociative agents, sometimes in combination with short-acting opioids  (
         <a class="graphic graphic_table graphicRef52744" href="/z/d/graphic/52744.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. Ideal medications for PSA have a rapid onset and short duration of action, maintain hemodynamic stability, and do not cause major side effects [
         <a href="#rid22">
          22
         </a>
         ]. Several medications are commonly used, and no single drug is ideal for every situation.
        </p>
        <p>
         In addition to PSA medications, use of non-opioid multimodal analgesia (eg,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         ) and local/regional anesthesia, if appropriate, can reduce pain levels, minimize dose of PSA medications, and decrease risk of post-procedural respiratory depression. (See
         <a class="medical medical_review" href="/z/d/html/133187.html" rel="external">
          "Nonopioid pharmacotherapy for acute pain in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/397.html" rel="external">
          "Overview of peripheral nerve blocks"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4271712916">
         <span class="h2">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         is a phenol derivative that provides effective PSA for emergency procedures [
         <a href="#rid22">
          22,23
         </a>
         ]. Propofol is highly lipophilic and therefore crosses the blood-brain barrier rapidly. Onset of sedation is within approximately 40 seconds, and its duration of action is approximately six minutes [
         <a href="#rid24">
          24,25
         </a>
         ]. Propofol acts as a sedative and amnestic but provides no analgesia. It can induce deep sedation rapidly and must be given with careful attention to dosing and monitoring. In addition to its use for PSA, propofol is used for long-term sedation in critically ill patients, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propofol'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – For PSA in adults,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         is given by slow injection in an initial loading dose of 0.5 to 1 mg/kg IV followed by doses of 0.25 to 0.5 mg/kg IV every one to three minutes as necessary until the appropriate level of sedation is achieved [
         <a href="#rid23">
          23
         </a>
         ]. One reasonable approach to administration is to give 20 mg every 10 seconds (eg, a 50 mg dose would be given over 25 seconds), although there is no direct evidence demonstrating improved efficacy or safety using this regimen.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older adults – In older adult patients, reduce the dose by 20 to 60 percent of a typical healthy young adult dose and administer slower, such as over three to five minutes [
         <a href="#rid26">
          26
         </a>
         ]. The initial bolus dose should not exceed 0.5 mg/kg [
         <a href="#rid15">
          15,16
         </a>
         ]. Plasma concentrations appear to be increased in older adult patients, which can lead to prolonged sedation and more pronounced cardiorespiratory depression. Patients over 55 are particularly sensitive [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="local">
          'Older adult patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired kidney or liver function – No dose adjustments are required for
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         in patients with impaired kidney or liver function [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity – A reasonable strategy when performing PSA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         in the patient with obesity is to give an initial dose based on the patient's adjusted body weight (AdjBW) (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ) and then give additional titrated doses as needed to achieve the desired level of sedation. Propofol's pharmacokinetics are highly dependent on cardiac output, which is elevated in patients with obesity. Propofol is also highly lipophilic and has a greater volume of distribution in patients with obesity. Both of these factors can lead to more rapid clearance and a shorter duration of effect. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Analgesic coadministration
         </strong>
         – Short-acting opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ) are commonly coadministered during PSA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . The decision to coadminister an analgesic should be individualized based on the patient's pre-procedure pain, expected pain course during and after the procedure, and risk of complications from administering a synergistic agent. Patients often receive analgesia while awaiting the PSA and procedure, and that may be sufficient if pain is adequately controlled. In many instances, patients experience little or no pain before, during, or after a procedure (eg, lumbar puncture, cardioversion) and little or no additional analgesia is necessary to supplement propofol. In procedures that lead to a substantial decrease in pain (eg, dislocation reduction), either no additional analgesic or a short-acting analgesic (eg, fentanyl) may be all that is needed, anticipating that the greatest risk of hypoventilation occurs immediately following relief of pain (eg, when the joint is reduced). In a trial of patients who had adequate analgesia with
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         prior to PSA, the combination of propofol and
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         did not improve pain levels compared with propofol alone, and the alfentanil group required more stimulation to induce respiration [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Short-acting opioids (fentanyl, others)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who are expected to have procedural pain and are at risk of hypoventilation, an alternative to short-acting opioids is pretreatment with a sub-dissociative dose of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , which appears to provide comparable analgesia with less risk of respiratory depression [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic reactions
         </strong>
         – Significant allergic reactions to the preparation of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         available in the Unites States and Canada appear to be rare even though the manufacturer lists egg or soybean allergies as contraindications to its use. A discussion on anaphylactic reactions to a previous formulation of propofol and allergic reactions to the current emulsion can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">
          "Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Hypnotic induction agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Potential side effects include hypotension (due to myocardial depression) and respiratory depression. These side effects generally resolve quickly and uneventfully because of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         's brief duration of action. However, hypotension can produce complications in patients with severe medical problems (eg, sepsis, cardiac dysfunction) or hypovolemia [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Respiratory depression usually manifests as a mild oxygen desaturation. Coadministration with other sedatives or analgesics (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ) can exacerbate respiratory problems. Episodes of hypoxia are generally insignificant, successfully treated with supplemental oxygen and patient stimulation, and less commonly require short periods of assisted ventilation with a bag-valve mask. Endotracheal intubation due to propofol-induced respiratory depression during PSA is not reported [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reducing injection site pain
         </strong>
         –
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          Propofol
         </a>
         injection through an IV catheter causes pain in up to 80 percent of patients, although the pain is typically mild and many patients do not recall the discomfort [
         <a href="#rid29">
          29,30
         </a>
         ]. Injecting through a larger venous catheter placed in the largest vein possible (eg, antecubital fossa) reduces the pain [
         <a href="#rid31">
          31,32
         </a>
         ]. Multiple methods to reduce pain have been studied, and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         has demonstrated the most consistent benefit. The small doses of lidocaine are unlikely to cause any significant cardiac or neurologic adverse effects. The following techniques are effective, but the venous occlusion technique was found to provide the best pain relief in a meta-analysis of randomized trials [
         <a href="#rid31">
          31,33
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Place a tourniquet proximal to the venipuncture site. Inject
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         1% 40 to 60 mg (0.5 to 1 mg/kg) into the vein. After 60 seconds, release the tourniquet and inject
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         .
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mix
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         1% 40 mg with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         200 mg in the same syringe and inject with or without vein occlusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pretreatment with multiple other agents, including
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         , opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ), steroids (eg,
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ),
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         ,
         <a class="drug drug_general" data-topicid="8591" href="/z/d/drug information/8591.html" rel="external">
          ketorolac
         </a>
         , and
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         , has been found to effectively reduce pain [
         <a href="#rid29">
          29,30,32,34-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency department use
         </strong>
         – Multiple trials and prospective studies have found
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         to be safe and effective for PSA in the emergency department [
         <a href="#rid15">
          15,24,44,45
         </a>
         ]. Evidence supports the safety and efficacy of nurse-administered propofol PSA, during which the only physician present is performing the procedure (eg, outpatient endoscopy) [
         <a href="#rid46">
          46-53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite the evidence above, not all clinicians who are qualified and wish to administer
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for PSA are allowed to do so. Reasons for this are complex and beyond the scope of this discussion but may include misunderstandings about patient safety as well as political and economic factors [
         <a href="#rid54">
          54,55
         </a>
         ]. The manufacturer's label states, "only those persons trained in the administration of general anesthesia should administer the drug," and goes on to state, "only those persons not involved in the conduct of the surgical/diagnostic procedure should administer the drug" [
         <a href="#rid56">
          56
         </a>
         ]. In the United States, these statements have led some nursing organizations to question whether nurses other than certified registered nurse anesthetists should administer propofol. However, nursing regulatory agencies are now actively involved in education, training, and certification of nurses to safely provide propofol PSA.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1239134507">
         <span class="h2">
          Etomidate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         , an imidazole derivative, is a sedative that is commonly used for PSA. Several randomized trials and prospective observational studies have found that etomidate is an effective sedation agent for PSA and does not cause major complications (eg, respiratory depression requiring endotracheal intubation) [
         <a href="#rid1">
          1,57-59
         </a>
         ]. However, myoclonus occurs with regularity, and procedure success rates may be lower when compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         . The use of etomidate for rapid sequence intubation is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/271.html" rel="external">
          "Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – For PSA in adults,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         is given IV over 30 to 60 seconds in doses of 0.1 to 0.15 mg/kg (which is lower than the rapid sequence intubation dose). It can be redosed at 0.05 mg/kg approximately every three to five minutes as needed. The onset of action of etomidate is almost immediate, and its duration of effect is 5 to 15 minutes [
         <a href="#rid1">
          1,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older adults or impaired kidney or liver function –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         can have more profound and prolonged effects in older patients and patients with renal or hepatic insufficiency [
         <a href="#rid60">
          60
         </a>
         ]. In such patients, doses in the lower dosing range should be used. An important benefit of etomidate is that it maintains cardiovascular stability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         has pharmacokinetic and pharmacodynamic properties similar to
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         . Thus, we suggest basing dosing on AdjBW (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ) with additional titrated doses given as needed [
         <a href="#rid61">
          61,62
         </a>
         ]. Actual body weight (ABW) dosing is recommended for tracheal intubation in patients with a BMI 30 to 39 kg/m
         <sup>
          2
         </sup>
         to prevent risk of underdosing (eg, awake while paralyzed), which is not a concern during PSA. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addition of analgesic agent
         </strong>
         –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         has no analgesic properties and often requires the coadministration of a short-acting opioid, such as
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , which increases the risk of respiratory depression [
         <a href="#rid4">
          4
         </a>
         ]. We suggest that not exceeding 0.5 mcg/kg fentanyl in any single dose when given with etomidate and keeping the total amount of fentanyl to a minimum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Potential side effects of
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         include myoclonus, respiratory depression, adrenal suppression, and nausea and vomiting. Myoclonus is the most frequently reported side effect. It is thought to be related to subcortical disinhibition and has been reported in up to 80 percent of patients who receive etomidate for PSA [
         <a href="#rid59">
          59,63-65
         </a>
         ]. The degree of myoclonus may be dose dependent and ranges from mild and transient to severe enough to prevent completion of the procedure [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myoclonus – Reports of severe myoclonus associated with PSA are rare. In such cases, we suggest immediate airway support and treatment with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         1 to 2 mg IV approximately every 60 seconds until myoclonus abates. Alternative benzodiazepines may be used if midazolam is unavailable. Small trials have shown a reduction of myoclonus in patients given a pretreatment
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         dose (0.03 to 0.05 mg/kg), a concurrent midazolam dose (0.015 mg/kg), or a pretreatment
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         dose (60 mg); however, these are not routinely used, and there is insufficient evidence to support any specific approach [
         <a href="#rid63">
          63,66,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory depression – Respiratory depression occurred in approximately 10 percent of cases in a systematic review of
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         for PSA [
         <a href="#rid57">
          57
         </a>
         ]. In this review, respiratory depression was defined as a fall in oxygen saturation below 90 percent or occurrence of apnea. There were no serious complications, and respiratory depression resolved quickly without major interventions in the great majority of cases. Nevertheless, clinicians must be prepared to support the patient's airway and breathing in the event of respiratory compromise, as is true whenever PSA is performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adrenal suppression –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         causes adrenal insufficiency when given by continuous infusion. Reductions in plasma cortisol concentrations have also been reported in patients receiving a single induction dose of etomidate [
         <a href="#rid68">
          68,69
         </a>
         ]. However, the clinical significance of transient reductions in cortisol in patients undergoing PSA with etomidate remains unclear. Most such patients are relatively healthy and receive a single sedating dose, and complications related to adrenal suppression have not been reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reducing injection site pain
         </strong>
         –
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          Etomidate
         </a>
         causes pain during injection into peripheral veins. Strategies similar to those used for
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         can be used to reduce such pain. (See
         <a class="local">
          'Propofol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H813457191">
         <span class="h2">
          Benzodiazepines (midazolam, others)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines are commonly used for minimal sedation (anxiolysis) but less often for deeper sedation due to the superior effectiveness of the ultra-short-acting agents
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         . Benzodiazepines produce anxiolysis and amnesia but have no analgesic properties. Compared with ultra-short-acting agents,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         has a longer duration of action that makes it better suited for anxiolysis than for PSA [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Midazolam
         </strong>
         –
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          Midazolam
         </a>
         is the benzodiazepine used most often for PSA. Because it is lipophilic, midazolam penetrates the blood-brain barrier quickly. Midazolam can be used alone for anxiolysis or in combination with short-acting opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ) for deeper levels of sedation and analgesia. Its time of onset is two to five minutes, and its duration of action is 30 to 60 minutes [
         <a href="#rid11">
          11,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          Midazolam
         </a>
         is usually given IV over one to two minutes in doses of 0.02 to 0.03 mg/kg. Often in adults, midazolam is given in individual doses of 0.5 or 1 mg and titrated to effect. No single dose should exceed 2.5 mg. Repeat doses may be given every two to five minutes as necessary. The total dose necessary for adequate sedation varies based upon many factors, including patient weight and age, medication tolerance, comorbidities, and the duration of the procedure. In most cases, PSA can be performed using no more than 5 mg of midazolam.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Anxiolysis - A single
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         dose of 0.02 mg/kg (approximately 1 to 2 mg) is usually sufficient.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Older adults or impaired kidney or liver function – Use lower doses, longer dosing intervals, and smaller total amounts to reduce the risk of prolonged sedation and delirium.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Obesity – We suggest using a standard, non-weight-based dose or AdjBW dose to determine the initial dose. Regardless of whether benzodiazepines are used alone or in combination with other medications, it is safer to administer smaller supplemental doses as needed until the desired effect is achieved [
         <a href="#rid62">
          62
         </a>
         ]. The half-life and volume of distribution of benzodiazepines increases with body weight, and so there is the potential for the medication and metabolites to accumulate with additional doses, potentially causing adverse effects such as oversedation and respiratory depression. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          Midazolam
         </a>
         can cause respiratory depression in high doses or when given concomitantly with other sedatives or opioids. With repeated doses, midazolam accumulates in adipose tissue, which can significantly prolong sedation [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other benzodiazepines
         </strong>
         -
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         are less suited for PSA due to their relatively prolonged onset and duration of action. They also have more side effects and inferior amnestic properties compared with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid11">
          11,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In 2020, the US Food and Drug Administration (FDA) approved
         <a class="drug drug_general" data-topicid="128915" href="/z/d/drug information/128915.html" rel="external">
          remimazolam
         </a>
         , an ultra-short-acting IV benzodiazepine, for induction and maintenance of sedation in adults undergoing procedures lasting ≤30 minutes. Its advantages, disadvantages, and potential uses are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults", section on 'Remimazolam'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3124866609">
         <span class="h2">
          Short-acting opioids (fentanyl, others)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Short-acting opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ) are often given alone or in combination with sedatives for PSA.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         is a synthetic opioid that was frequently used in combination with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         to provide analgesia during PSA before
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         became widely available. It has 75 to 125 times the potency of
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         , a rapid onset of action (two to three minutes), and a short duration of effect (30 to 60 minutes) but has no amnestic properties [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          Remifentanil
         </a>
         and
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         are opioids similar in structure to
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         with a rapid onset and duration of action of approximately five minutes, and both are used for PSA [
         <a href="#rid72">
          72,73
         </a>
         ]. The potency of remifentanil and fentanyl are comparable, but alfentanil is one-fifth to one-tenth as potent. Remifentanil can be given in combination with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for PSA [
         <a href="#rid74">
          74-76
         </a>
         ]. Few studies have assessed alfentanil as a sole agent for PSA, and there are no published guidelines for its use in this manner. There is no evidence that PSA using remifentanil and propofol is superior to propofol alone, nor is there evidence that either remifentanil or alfentanil is superior to fentanyl.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fentanyl adjunct – When used in combination with a sedative for PSA,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         is usually given by slow IV push in doses of 0.5 mcg/kg every two minutes until an appropriate level of sedation and analgesia is achieved [
         <a href="#rid11">
          11
         </a>
         ]. The maximum total dose is generally 5 mcg/kg or approximately 250 mcg, but higher doses may be needed in some instances.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Remifentanil adjunct – When used in combination with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for PSA,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         is given in a dose of 0.5 mcg/kg (and propofol 0.5 mg/kg) over one minute [
         <a href="#rid75">
          75
         </a>
         ]. Subsequent doses of remifentanil 0.25 mcg/kg and propofol 0.25 mg/kg may be given approximately every one to two minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Remifentanil alone – When
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         is used
         <strong>
          alone
         </strong>
         for PSA, the initial dose is 0.5 to 3 mcg/kg, and subsequent doses of 0.25 to 1 mcg/kg may be given approximately every two minutes as needed [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alfentanil adjunct –
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          Alfentanil
         </a>
         may be used as an adjunct for PSA with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and is given in a dose of 2.5 mcg/kg (along with propofol 0.5 mg/kg). Both may be repeated approximately every two minutes as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older adults or impaired kidney or liver function – Use lower doses, longer dosing intervals, and smaller total amounts to reduce the risk of prolonged sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity – We suggest using a standard, non-weight-based dose or AdjBW dose to determine the initial dose of
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         , and
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         , then titrating to clinical effect. Doses based on ABW increase the risk for respiratory depression, hypotension, and bradycardia [
         <a href="#rid61">
          61,62
         </a>
         ]. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The primary side effect of opioids is respiratory depression, which is potentiated by the coadministration of sedatives.
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          Fentanyl
         </a>
         rarely causes hypotension and does not stimulate histamine release. Older patients and patients with renal or hepatic disease can experience more prolonged or profound effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective study of 148 adults given
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         for PSA, 58 (39 percent) developed minor respiratory complications requiring intervention (eg, increased oxygen, brief bag-mask ventilation) despite achieving lighter levels of sedation than typically reached with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H58610879">
         <span class="h2">
          Coadministration of midazolam and fentanyl
         </span>
         <span class="headingEndMark">
          —
         </span>
         In settings where ultra-short-acting agents are unavailable or a longer duration of PSA is required (eg, gastrointestinal endoscopy), the combination of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         is sometimes used for PSA [
         <a href="#rid10">
          10,78-80
         </a>
         ]. The combination of midazolam and fentanyl can cause hypoxia and apnea and may require airway intervention and medication reversal [
         <a href="#rid10">
          10,11
         </a>
         ]. To minimize the risk of respiratory depression, we suggest administering midazolam first and then titrating fentanyl carefully, but either sequence is acceptable. Regardless of the sequence, clinicians must titrate these medications carefully to minimize the risk of oversedation and respiratory compromise.
        </p>
        <p>
         A reasonable approach to dosing these medications when they are used together is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         first: 0.02 mg/kg (maximum 2 mg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wait two minutes and observe patient response; give second dose of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         if necessary
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Give
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         0.5 mcg/kg
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Observe patient; may repeat
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         dose every two minutes as necessary; titrate to effect
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use smaller doses and longer intervals between doses in older patients and patients with compromised hepatic or renal function
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1670840559">
         <span class="h2">
          Ketamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         For PSA,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         can be used to provide sedation either as a single agent or premixed with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         in a single syringe ("ketofol"), or to provide analgesia instead of an opioid (typically combined with propofol but not premixed in a single syringe).
        </p>
        <p class="headingAnchor" id="H2988037047">
         <span class="h3">
          Ketamine sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         , a phencyclidine derivative that acts as a dissociative sedative, is commonly used in pediatric PSA and has gained acceptance for adult PSA. It produces a trance-like state and provides sedation, analgesia, and amnesia while preserving upper airway muscle tone, airway protective reflexes, and spontaneous breathing. Because of its rapid onset, relatively short duration of effect (10 to 20 minutes), and excellent sedative and analgesic properties, it is often used for painful procedures such as fracture reduction or laceration repair [
         <a href="#rid4">
          4,81
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         may be preferable to
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         when hypotension is a particular concern, in patients who may have developed a significant tolerance to GABAergic agents (whereas ketamine would not need titration), for lengthier procedures (ie, longer than 5 to 10 minutes), and when maintaining airway protective reflexes may be critical.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         can exacerbate schizophrenia and should be avoided in patients with this condition [
         <a href="#rid82">
          82,83
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – For PSA in adults, a dose of 1 to 2 mg/kg is given IV over one to two minutes. Subsequent doses of 0.25 to 1 mg/kg may be repeated every 5 to 10 minutes thereafter. If
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is being used as a single agent for sedation, the subsequent doses are usually at the higher end of the range, typically 0.5 to 1 mg/kg. If ketamine is being used in combination with other agents, subsequent doses are at the lower end of the range, typically 0.25 to 0.5 mg/kg. Ketamine can also be given intramuscularly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As with any sedative, the decision about appropriate repeat doses should take into consideration the effect of the initial dose, the duration of the procedure, and the depth of sedation required for its completion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired kidney or liver function – No dose adjustments are required for
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         in patients with impaired kidney or liver function.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity – We suggest using AdjBW (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ) to determine the initial dosing of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA with additional titrated doses provided as needed [
         <a href="#rid62">
          62
         </a>
         ]. There is insufficient evidence to determine the best dosing regimen for ketamine when used for PSA in patients with obesity. Basing dose on ABW may increase the risk of side effects and oversedation, but some experts would recommend ABW dosing in patients with a BMI 30 to 39 kg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventing and managing adverse effects
         </strong>
         – The reported side effects of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         include tachycardia, hypertension, emergence reactions, nausea, vomiting, laryngospasm, hypersalivation, and increased intracranial and intraocular pressure [
         <a href="#rid4">
          4,85-87
         </a>
         ]. Tachycardia and hypertension (from increased sympathetic tone) are generally mild and transient, and significant cardiorespiratory events are rare. There is theoretical concern that ketamine could cause myocardial ischemia in patients with underlying coronary artery disease. Serious adverse reactions rarely occur when ketamine is used for PSA in adults according to a systematic review of 87 studies involving over 70,000 patients [
         <a href="#rid85">
          85
         </a>
         ]. Anticipated adverse effects can be mitigated as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Emergence reactions
         </strong>
         – These are the most commonly reported side effects of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , occurring in up to 20 percent of adults [
         <a href="#rid85">
          85
         </a>
         ]. We believe that the decision to use pretreatment versus to intervene, if necessary, when a reaction occurs can be left to the clinician's discretion. These reactions vary in their intensity and have been described as disorientation, dreamlike experiences, or hallucinations that may be frightening. Although disturbing in some cases, emergence reactions are often benign and self-limited, requiring no pharmacologic treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Emergence reactions can be prevented with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         pretreatment [
         <a href="#rid22">
          22,85,88-91
         </a>
         ]. A typical adult IV pretreatment dose of midazolam is 2 to 4 mg (approximately 0.05 mg/kg) given slowly (over about two minutes) prior to administering
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         . An alternative agent is
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (5 mg), which was found to produce a comparable reduction in emergence reactions in a small randomized trial [
         <a href="#rid92">
          92
         </a>
         ]. When given as pretreatments for emergence delirium, midazolam and haloperidol appear to cause no adverse clinical effects, but both slightly prolong recovery time (17 and 32 minutes, respectively) [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Emergence reactions, when they do occur, can be promptly and effectively treated with small doses of benzodiazepines such as
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pretreatment with antiemetic
         </strong>
         – Pretreatment with
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         or comparable agents may be helpful to prevent nausea and vomiting associated with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         administration that occurs in approximately 4 percent of adults. Nausea and vomiting usually occur when the patient is awake and alert and thus probably do not predispose the patient to aspiration. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preventing laryngospasm
         </strong>
         – Laryngospasm is a rare complication, occurring more frequently in children than adults, and is typically either transient or improves with bag-mask ventilation. We agree with guidelines published by the American College of Emergency Physicians that recommend minimizing triggers of laryngospasm in patients receiving
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA, such as preventing secretions or blood from accumulating in the posterior oropharynx and avoiding excessive stimulation of the oropharynx with suction devices or other instruments [
         <a href="#rid87">
          87
         </a>
         ]. The risk of laryngospasm may be greater in patients with anatomic abnormalities of the upper airway (eg, tracheal stenosis, tracheomalacia) or those undergoing procedures involving significant or prolonged stimulation of the oropharynx.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pretreatment with anticholinergic not needed
         </strong>
         – Hypersalivation commonly occurs from
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         but is rarely of clinical significance in adult patients. There is no established benefit of premedicating with
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         or
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         to prevent the hypersalivation associated with ketamine [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3084862687">
         <span class="h3">
          Ketamine analgesia for sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         coadministered during PSA in sub-dissociative dosing (0.25 to 0.5 mg/kg bolus, maximum bolus 35 mg), as compared with opioids, can provide adequate analgesia with possibly fewer complications. Trials suggest that adding ketamine to
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         provides more consistent sedation, reduces pain, decreases the need for post-procedural analgesics, results in fewer episodes of desaturation, and requires smaller cumulative doses of propofol [
         <a href="#rid95">
          95,96
         </a>
         ]. A small trial found that patients given ketamine (0.3 mg/kg IV) and propofol during PSA achieved similar analgesia but experienced five-times fewer complications (eg, hypoxia) compared with patients given
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         (1.5 mcg/kg IV) and propofol [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3995352657">
         <span class="h3">
          Premixed with propofol (ketofol)
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Ketofol," which refers to a 1:1 mixture of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         for use in PSA, purportedly reduces the risk for potential side effects (eg, propofol-induced hypotension and ketamine-induced vomiting and emergence reactions) since the two medications act synergistically, thus allowing lower doses of each as well as increasing ease of administration [
         <a href="#rid97">
          97,98
         </a>
         ]. There is no standard for mixing or dose regimen; a common approach is to mix 10 mg/mL ketamine and 10 mg/mL propofol into a 20-mL syringe. The initial dose is 0.375 to 0.5 mg/kg (0.0375 to 0.05 mL/kg of this mixture), and half of this dose can be repeated as needed.
        </p>
        <p>
         However, some of the better-designed studies of ketofol have shown that this combination therapy is not more efficacious or safer (ie, improving clinically significant outcomes or reducing important complications) than
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         alone, but it may provide a more consistent level of sedation [
         <a href="#rid3">
          3,96,99-102
         </a>
         ]. Additionally, by not premixing these agents, even though administration is not as simple, ketamine premedication can still be given in a sub-dissociative dose followed by titrating propofol as a single agent. (See
         <a class="local">
          'Ketamine analgesia for sedation'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of patients given ketofol compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         alone for PSA in emergency departments (6 trials, 932 patients) found fewer adverse respiratory events from ketofol (29.0 versus 35.4 percent, RR 0.82, 95% CI 0.68-0.99) [
         <a href="#rid103">
          103
         </a>
         ]. However, many of these adverse events were not clinically important (eg, brief oxygen desaturation), and the review found no significant difference in the overall rate of adverse events or in the time required to complete procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another meta-analysis of patients given ketofol compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         alone for PSA not limited to the emergency department setting (18 trials, 1917 patients) found that ketofol caused less respiratory depression requiring intervention (14 trials, 6.0 versus 11.5 percent, RR 0.47, 95% CI 0.31-0.70) and less bradycardia (8 trials, 2.4 versus 6.5 percent, RR 0.47, 95% CI 0.27-0.82) and hypotension (9 trials, 2.3 versus 8.7 percent, RR 0.41, 95% CI 0.17-0.97) [
         <a href="#rid104">
          104
         </a>
         ]. Although the interventions required to correct respiratory problems were not described, transient respiratory depression, bradycardia, or hypotension in patients receiving PSA in the emergency department is generally not considered clinically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized, double-blind, multicenter trial of ketofol compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         alone for PSA in the emergency department included 573 patients (powered to detect 10 percent difference) and found no clinically significant differences in the primary outcome of respiratory adverse events (desaturation, apnea, or hypoventilation) that required an intervention (3 versus 5 percent) [
         <a href="#rid105">
          105
         </a>
         ]. Patients receiving ketofol were less likely to have hypotensive events (1 versus 8 percent) but more likely to experience severe emergence delirium (5 versus 2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized, double-blind trial of ketofol compared with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         alone for PSA in a community hospital emergency department setting included 284 patients and found no clinically significant difference in the primary outcome of respiratory adverse events (30 versus 32 percent) [
         <a href="#rid106">
          106
         </a>
         ]. Three patients receiving ketofol and one patient receiving propofol required bag-mask ventilation. Patients receiving ketofol had more consistent sedation and received fewer repeat doses (46 versus 65 percent), but these did not appear to be important clinical differences. Patients given ketofol had less agitation during the procedure (3.5 versus 10.5 percent), while the opposite was true during recovery (7 versus 5 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2129581139">
         <span class="h2">
          Dexmedetomidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         as a sole agent for PSA generally does not have significant advantages compared with other sedatives with regards to efficacy and side effects. Dexmedetomidine PSA may be a reasonable choice when loss of the airway would be catastrophic (eg, potentially difficult airway) or when tachycardia or hypertension would be particularly dangerous. Sedation with dexmedetomidine is characterized by generally preserved muscle tone and respiratory effort (even at 10 times the maximum recommended dosage), spontaneous movement, and easy arousal, enabling the patient to obey simple instructions [
         <a href="#rid107">
          107-111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is an alpha agonist that acts at the locus coeruleus in the pons to reduce release of norepinephrine, resulting in sedation that is more similar to a natural sleep-like state than sedation produced by GABAergic agents (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , benzodiazepines). It appears to reduce pain through modulation of alpha receptors in the spinal cord [
         <a href="#rid112">
          112,113
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – When used as a sedative agent (ie, mechanically ventilated patients),
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         is usually given as an infusion at a rate of 0.2 to 1 mcg/kg/hour. A bolus of 0.5 to 1 mcg/kg can be given over 10 minutes prior to starting infusion. Dexmedetomidine can also be given intranasally in doses of 2 to 3 mcg/kg for anxiolysis and sedation when other routes of administration are felt not to be optimal choices [
         <a href="#rid114">
          114,115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         (same dose as above) combined with
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         (1 to 2 mg/kg) provided effective procedural sedation while minimizing cardiovascular depression in several small trials [
         <a href="#rid116">
          116-118
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired kidney or liver function – Lower starting doses are recommended in patients with liver disease but not with kidney disease [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obesity - We suggest using AdjBW (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ) to determine the dosing of
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         for PSA [
         <a href="#rid62">
          62,120
         </a>
         ]. Dexmedetomidine's pharmacodynamics and pharmacokinetics differ in patients with obesity, and lower doses are needed to reach a given plasma concentration and level of sedation. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <strong>
         </strong>
         Although uncommon, potentially serious events include decreased respiratory drive and airway obstruction [
         <a href="#rid121">
          121-124
         </a>
         ]. Dose-dependent bradycardia and hypotension can occur, although hypertension may be seen initially during high-dose infusion due to stimulation of alpha 2B receptors [
         <a href="#rid112">
          112
         </a>
         ]. Small observational studies have found that
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         , when used alone, may provide unpredictable degrees of amnesia and sedation as well as unacceptable levels of bradycardia and hypotension, often requiring termination of the procedure or use of adjunctive sedatives [
         <a href="#rid125">
          125,126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1523281755">
         <span class="h2">
          Barbiturates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Barbiturates cause sedation by suppressing the reticular activating center in the brainstem and cerebral cortex.
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          Methohexital
         </a>
         and thiopental are barbiturates occasionally used for PSA.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Methohexital
         </strong>
         – This is the most commonly used barbiturate for PSA but has largely been supplanted by
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         .
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          Methohexital
         </a>
         has immediate onset and a duration of action less than 10 minutes, and it provides sedation and amnesia but no analgesia. It is often given in combination with opioids. One small randomized trial found methohexital and propofol to have comparable safety and efficacy when used for fracture and dislocation reduction [
         <a href="#rid127">
          127
         </a>
         ]. A small study found methohexital to have similar efficacy and hemodynamic changes compared with propofol and etomidate when used for electrical cardioversion in the emergency department [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dosing
         </strong>
         – The initial dose of
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         is 0.75 to 1 mg/kg given IV; repeat doses of 0.5 mg/kg IV can be given every two minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Older adults or impaired kidney or liver function – Use lower doses, longer dosing intervals, and smaller total amounts.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Obesity – We suggest using IBW to calculate the initial doses of
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         with additional titrated doses given as needed to achieve adequate sedation [
         <a href="#rid129">
          129
         </a>
         ]. Patients with obesity have increased cardiac output, leading to more rapid redistribution and thus more rapid awakening after a single bolus dose [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          Methohexital
         </a>
         causes myocardial depression, which can lead to hypotension and tachycardia. Methohexital can cause respiratory depression, especially when coadministered with opioids. Unlike other barbiturates, methohexital can precipitate or exacerbate seizures and should be avoided in patients with a seizure disorder [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thiopental
         </strong>
         – This barbiturate is used for induction of general anesthesia and rarely used in the performance of PSA. It is similar in efficacy and side effects to
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         but suppresses seizures. Dosing in patients with obesity, older adults, or patients with impaired kidney or liver function is similar to methohexital.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H431321412">
         <span class="h2">
          Nitrous oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) is an ultra-short-acting agent used for PSA that is inhaled as a 30 to 50 percent mixture combined with 30 percent oxygen to avoid hypoxemia. N
         <sub>
          2
         </sub>
         O has an immediate onset of action and provides analgesia, anxiolysis, and sedation and does not require IV access. The major disadvantage to N
         <sub>
          2
         </sub>
         O is that it must be administered in a well-ventilated room with a scavenging system to prevent clinician exposure [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Studies in children have generally found N
         <sub>
          2
         </sub>
         O to be safe, but it may not provide adequate analgesia for more painful procedures such as fracture reduction. N
         <sub>
          2
         </sub>
         O has been safely used for decades for labor pain in Great Britain, Scandinavia, Australia, New Zealand, Canada, and other countries but less commonly in the United States. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Nitrous oxide'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4468.html" rel="external">
          "Pharmacologic management of pain during labor and delivery", section on 'Nitrous oxide'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2088487846">
         <span class="h1">
          DISCHARGE CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain conditions should be met before a patient can be considered safe for discharge following PSA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms such as pain, lightheadedness, and nausea should be well controlled
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital signs and respiratory and cardiac function should be stable
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental status and physical function should have returned to a point where the patient can care for themselves with minimal to no assistance
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A reliable person who can provide support and supervision should be present at the patient's home for at least a few hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring of complications from the procedure itself is unnecessary
        </p>
        <p>
        </p>
        <p>
         Clear written discharge instructions should be given and explained to the patient and to the family member or other person who will be assisting with the patient's care following PSA. The clinician should explain what was done, the expected course, potential problems, what to do if problems arise, when and where to follow up, and when to return to normal activities. Inform the patient that it is not uncommon to experience mild symptoms such as nausea, lightheadedness, fatigue, or unsteadiness for up to 24 hours [
         <a href="#rid131">
          131-133
         </a>
         ]. The patient should be instructed to avoid driving a motor vehicle, operating machinery, or consuming alcohol until the following day. Even though several small studies have shown that baseline neuromotor function may return as quickly as two hours after
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         PSA, their results are insufficient to recommend rapid return to operating a motor vehicle or dangerous machinery [
         <a href="#rid134">
          134-136
         </a>
         ].
        </p>
        <p>
         Some clinicians believe that patients can be safely discharged within 30 minutes of receiving their last dose of sedative, even if they have not entirely returned to baseline (eg, still exhibit mild drowsiness), provided that no significant adverse events occurred during the procedure, they did not receive a reversal agent (eg,
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">
          flumazenil
         </a>
         ), and a reliable person is available to provide support. A study of 1341 pediatric patients undergoing PSA with longer-acting agents (ie,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ) found that almost all new adverse post-sedation events (eg, hypoxia, hypotension) occurred within 25 minutes of the last dose of sedative administration [
         <a href="#rid137">
          137
         </a>
         ]. Rarely, episodes of hypoxia developed up to 40 minutes after the last medication dose, but in all such cases, these had been preceded by a prior episode of hypoxia. Given these findings, it is unlikely that a longer period of observation would be necessary following PSA with ultra-short-acting agents [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1323855439">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120318.html" rel="external">
          "Society guideline links: Procedural sedation in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2890903154">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choosing a medication
         </strong>
         – Ideal medications for procedural sedation and analgesia (PSA) have a rapid onset and short duration of action, maintain hemodynamic stability, and do not cause major side effects. No single drug is ideal for all situations. Medications used for PSA include
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">
          methohexital
         </a>
         ; dosing, onset, duration, and common adverse effect are presented in the table  (
         <a class="graphic graphic_table graphicRef52744" href="/z/d/graphic/52744.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Choosing a medication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients without increased risk
         </strong>
         – In patients without major comorbidities or hemodynamic instability, we suggest that PSA be performed using
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Both medications are safe and effective and possess similar times to onset and recovery, but propofol may result in a higher procedural success rate because it causes less myoclonus compared with etomidate. (See
         <a class="local">
          'Preferred medications in healthy patients: Propofol or etomidate'
         </a>
         above and
         <a class="local">
          'Propofol'
         </a>
         above and
         <a class="local">
          'Etomidate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         "Ketofol" (1:1 mixture of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ) is an alternative option that is not more efficacious or safer than propofol or ketamine alone but may provide a more consistent level of sedation (eg, fewer repeat sedative doses, less procedural agitation). By not premixing ketamine and propofol, even though administration is not as simple, ketamine premedication can still be given followed by titrating propofol as a single agent. (See
         <a class="local">
          'Premixed with propofol (ketofol)'
         </a>
         above and
         <a class="local">
          'Propofol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In settings where
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         are unavailable or a longer duration of PSA is required (eg, gastrointestinal endoscopy), a combination of
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         and
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         are commonly used, and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         is also a reasonable option. (See
         <a class="local">
          'Coadministration of midazolam and fentanyl'
         </a>
         above and
         <a class="local">
          'Ketamine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Older patients
         </strong>
         – Regardless of the sedative, administer using a lower starting dose and with slower rates of administration and less frequent dosing intervals since older patients are at increased risk of complications during PSA. The initial bolus dose of
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         should not exceed 0.5 mg/kg. (See
         <a class="local">
          'Older adult patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with obesity
         </strong>
         – Adjustments in the dosing of medications used for PSA should generally be based on ideal, adjusted, or lean body weight to avoid oversedation and are described in detail in the text. (See
         <a class="local">
          'Patients with obesity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients at risk of hypotension
         </strong>
         – In patients at risk of hypotension, we suggest using either
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA instead of another sedative (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Either agent will maintain hemodynamic stability. (See
         <a class="local">
          'Patients at risk for hypotension'
         </a>
         above and
         <a class="local">
          'Etomidate'
         </a>
         above and
         <a class="local">
          'Ketamine sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with potentially difficult airway
         </strong>
         – In patients who may have a potentially difficult airway or have compromised respiratory function, we suggest using
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         for PSA instead of another sedative (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Ketamine allows the patient to maintain protective airway reflexes and does not cause respiratory depression.
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is an alternative option since it generally preserves muscle tone and respiratory effort. (See
         <a class="local">
          'Patients at risk for airway or respiratory complications'
         </a>
         above and
         <a class="local">
          'Ketamine sedation'
         </a>
         above and
         <a class="local">
          'Dexmedetomidine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with major medical conditions
         </strong>
         – Conditions such as heart failure, chronic obstructive pulmonary disease, and neuromuscular diseases (ie, correlating with an American Society of Anesthesiologists [ASA] physical status classification of class III or greater)  (
         <a class="graphic graphic_table graphicRef87504" href="/z/d/graphic/87504.html" rel="external">
          table 3
         </a>
         ) place patients at increased risk for adverse events with PSA. Similar to older patients, regardless of the sedative chosen for PSA, use a lower starting dose, slower rates of administration, and repeat dosing at less frequent intervals. (See
         <a class="local">
          'Patients with major medical conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coadministration of analgesics
         </strong>
         – The decision to coadminister an analgesic should be individualized based on the patient's pre-procedure pain, expected pain course during and after the procedure, and risk of complications from administering a synergistic agent. Short-acting opioids (eg,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9347" href="/z/d/drug information/9347.html" rel="external">
          alfentanil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9854" href="/z/d/drug information/9854.html" rel="external">
          remifentanil
         </a>
         ) are often given in combination with sedatives that provide no analgesia (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         , benzodiazepines).
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         administered in sub-dissociative dosing (0.25 to 0.5 mg/kg bolus, maximum bolus 35 mg) is another analgesic option that does not have the risk of respiratory depression that occurs with opioids. (See
         <a class="local">
          'Short-acting opioids (fentanyl, others)'
         </a>
         above and
         <a class="local">
          'Ketamine analgesia for sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discharge criteria
         </strong>
         – Criteria for safe discharge following PSA include the following (see
         <a class="local">
          'Discharge criteria'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms such as pain, lightheadedness, and nausea should be well-controlled
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vital signs and respiratory and cardiac function should be stable
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mental status and physical function should have returned to a point where the patient can care for themselves with minimal to no assistance
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A reliable person who can provide support and supervision should be present at the patient's home for at least a few hours
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring of complications from the procedure itself is unnecessary
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Danahy M, Moch A, Biros M. Randomized clinical trial of etomidate versus propofol for procedural sedation in the emergency department. Ann Emerg Med 2007; 49:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillies GW, Lees NW. The effects of speed of injection on induction with propofol. A comparison with etomidate. Anaesthesia 1989; 44:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM. Research advances in procedural sedation and analgesia. Ann Emerg Med 2007; 49:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown TB, Lovato LM, Parker D. Procedural sedation in the acute care setting. Am Fam Physician 2005; 71:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plewa MC, King R, Johnson D, et al. Etomidate use during emergency intubation of trauma patients. Am J Emerg Med 1997; 15:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kociszewski C, Thomas SH, Harrison T, Wedel SK. Etomidate versus succinylcholine for intubation in an air medical setting. Am J Emerg Med 2000; 18:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi GJ, Kang H, Baek CW, et al. Etomidate versus propofol sedation for electrical external cardioversion: a meta-analysis. Curr Med Res Opin 2018; 34:2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MG, Park SW, Kim JH, et al. Etomidate versus propofol sedation for complex upper endoscopic procedures: a prospective double-blinded randomized controlled trial. Gastrointest Endosc 2017; 86:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adinehmehr L, Shetabi H, Moradi Farsani D, et al. Comparison of the Sedation Quality of Etomidate, Propofol, and Midazolam in Combination with Fentanyl During Phacoemulsification Cataract Surgery: A Double-Blind, Randomized, Controlled, Clinical Trial. Anesth Pain Med 2019; 9:e87415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2005; 45:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. Emerg Med Clin North Am 2005; 23:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JH, Miner JR, Shipley ER, et al. Propofol for emergency department procedural sedation and analgesia: a tale of three centers. Acad Emerg Med 2006; 13:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guenther E, Pribble CG, Junkins EP Jr, et al. Propofol sedation by emergency physicians for elective pediatric outpatient procedures. Ann Emerg Med 2003; 42:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coll-Vinent B, Sala X, Fernández C, et al. Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med 2003; 42:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newstead B, Bradburn S, Appelboam A, et al. Propofol for adult procedural sedation in a UK emergency department: safety profile in 1008 cases. Br J Anaesth 2013; 111:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homfray G, Palmer A, Grimsmo-Powney H, et al. Procedural sedation of elderly patients by emergency physicians: a safety analysis of 740 patients. Br J Anaesth 2018; 121:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss BS, Andolfatto G, Krauss BA, et al. Characteristics of and Predictors for Apnea and Clinical Interventions During Procedural Sedation. Ann Emerg Med 2016; 68:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soleimanpour H, Safari S, Rahmani F, et al. Intravenous hypnotic regimens in patients with liver disease; a review article. Anesth Pain Med 2015; 5:e23923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arulkumaran N, Montero RM, Singer M. Management of the dialysis patient in general intensive care. Br J Anaesth 2012; 108:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawfic QA, Bellingham G. Postoperative pain management in patients with chronic kidney disease. J Anaesthesiol Clin Pharmacol 2015; 31:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sladen, RN . Perioperative Care for the Patient with Renal or Hepatic Disease. Anesthesia &amp; Analgesia 2001; 92:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KA, Andolfatto G, Miner JR, et al. Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update. Ann Emerg Med 2019; 73:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Burton JH. Clinical practice advisory: Emergency department procedural sedation with propofol. Ann Emerg Med 2007; 50:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson ER, Seaberg DC, Mathias S. The use of propofol for sedation in the emergency department. Acad Emerg Med 1996; 3:234.
          </a>
         </li>
         <li class="breakAll">
          Diprivan (propofol): manufacturer's package insert. US National Library of Medicine www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=4756#section-11 (Accessed on May 26, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. Br J Anaesth 1998; 81:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Gray RO, Stephens D, Biros MH. Randomized clinical trial of propofol with and without alfentanil for deep procedural sedation in the emergency department. Acad Emerg Med 2009; 16:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee M, Kwon T, Kim S, et al. Comparative evaluation of the effect of remifentanil and 2 different doses of esmolol on pain during propofol injection: A double-blind, randomized clinical consort study. Medicine (Baltimore) 2017; 96:e6288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Wu L, Zhang C, Sun L. Is propofol injection pain really important to patients? BMC Anesthesiol 2017; 17:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jalota L, Kalira V, George E, et al. Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ 2011; 342:d1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasinwong W, Termthong S, Plansangkate P, et al. A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study. BMC Anesthesiol 2022; 22:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim DH, Chae YJ, Chang HS, et al. Intravenous lidocaine pretreatment with venous occlusion for reducing microemulsion propofol induced pain: comparison of three doses of lidocaine. J Int Med Res 2014; 42:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii Y, Itakura M. A comparison of pretreatment with fentanyl and lidocaine preceded by venous occlusion for reducing pain on injection of propofol: a prospective, randomized, double-blind, placebo-controlled study in adult Japanese surgical patients. Clin Ther 2009; 31:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi YJ, Park HS, Lee H, Yoon SZ. Single pretreatment of remifentanil may reduce pain after propofol and rocuronium injection in rapid sequence induction. Korean J Anesthesiol 2012; 63:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadav M, Durga P, Gopinath R. Role of hydrocortisone in prevention of pain on propofol injection. J Anaesthesiol Clin Pharmacol 2011; 27:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shivanna S, Priye S, Singh D, et al. Efficacy of methylprednisolone and lignocaine on propofol injection pain: A randomised, double-blind, prospective study in adult cardiac surgical patients. Indian J Anaesth 2016; 60:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad S, De Oliveira GS Jr, Fitzgerald PC, McCarthy RJ. The effect of intravenous dexamethasone and lidocaine on propofol-induced vascular pain: a randomized double-blinded placebo-controlled trial. Pain Res Treat 2013; 2013:734531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pei S, Zhou C, Zhu Y, Huang B. Efficacy of ondansetron for the prevention of propofol injection pain: a meta-analysis. J Pain Res 2017; 10:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadawy I, Ertok E, Boker A. Painless injection of propofol: pretreatment with ketamine vs thiopental, meperidine, and lidocaine. Middle East J Anaesthesiol 2007; 19:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nimmaanrat S, Jongjidpranitarn M, Prathep S, Oofuvong M. Premedication with oral paracetamol for reduction of propofol injection pain: a randomized placebo-controlled trial. BMC Anesthesiol 2019; 19:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang YW, Buerkle H, Lee TH, et al. Effect of pretreatment with ketorolac on propofol injection pain. Acta Anaesthesiol Scand 2002; 46:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akgün Salman E, Titiz L, Akpek E, Arslan G. Pretreatment with a very low dose of intravenous esmolol reduces propofol injection pain. Agri 2013; 25:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black E, Campbell SG, Magee K, Zed PJ. Propofol for procedural sedation in the emergency department: a qualitative systematic review. Ann Pharmacother 2013; 47:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakai A, Blackburn C, McCabe A, et al. The use of propofol for procedural sedation in emergency departments. Cochrane Database Syst Rev 2015; :CD007399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker JA, McIntyre RD, Schleinitz PF, et al. Nurse-administered propofol sedation without anesthesia specialists in 9152 endoscopic cases in an ambulatory surgery center. Am J Gastroenterol 2003; 98:1744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohda G, Higashi S, Sakumoto H, et al. Efficacy and safety of nurse-administered propofol sedation during emergency upper endoscopy for gastrointestinal bleeding: a prospective study. Endoscopy 2006; 38:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex DK, Heuss LT, Walker JA, Qi R. Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy. Gastroenterology 2005; 129:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato M, Horiuchi A, Tamaki M, et al. Safety and Effectiveness of Nurse-Administered Propofol Sedation in Outpatients Undergoing Gastrointestinal Endoscopy. Clin Gastroenterol Hepatol 2019; 17:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosslet GT, Devito ML, Lahm T, et al. Nurse-administered propofol sedation: feasibility and safety in bronchoscopy. Respiration 2010; 79:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKenzie P, Fang J, Davis J, et al. Safety of endoscopist-directed nurse-administered balanced propofol sedation in patients with severe systemic disease (ASA class III). Gastrointest Endosc 2021; 94:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slagelse C, Vilmann P, Hornslet P, et al. Nurse-administered propofol sedation for gastrointestinal endoscopic procedures: first Nordic results from implementation of a structured training program. Scand J Gastroenterol 2011; 46:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crego N. Procedural Sedation Practice: A Review of Current Nursing Standards. J Nurs Regul 2015; 6:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Krauss B. Barriers to propofol use in emergency medicine. Ann Emerg Med 2008; 52:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flynn G. "Poachers and dabblers?": ASA president's incautious comment riles emergency physicians. Ann Emerg Med 2007; 50:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weaver JM. The great debate on nurse-administered propofol sedation (NAPS)--where should we stand? Anesth Prog 2006; 53:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk J, Zed PJ. Etomidate for procedural sedation in the emergency department. Ann Pharmacother 2004; 38:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacchetti A, Senula G, Strickland J, Dubin R. Procedural sedation in the community emergency department: initial results of the ProSCED registry. Acad Emerg Med 2007; 14:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keim SM, Erstad BL, Sakles JC, Davis V. Etomidate for procedural sedation in the emergency department. Pharmacotherapy 2002; 22:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valk BI, Struys MMRF. Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet 2021; 60:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingrande J, Lemmens HJ. Anesthetic Pharmacology and the Morbidly Obese Patient. Curr Anesthesiol Rep 2013; 3:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. Crit Care 2020; 24:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doenicke AW, Roizen MF, Kugler J, et al. Reducing myoclonus after etomidate. Anesthesiology 1999; 90:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burton JH, Bock AJ, Strout TD, Marcolini EG. Etomidate and midazolam for reduction of anterior shoulder dislocation: a randomized, controlled trial. Ann Emerg Med 2002; 40:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruth WJ, Burton JH, Bock AJ. Intravenous etomidate for procedural sedation in emergency department patients. Acad Emerg Med 2001; 8:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hüter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion. Anesth Analg 2007; 105:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guler A, Satilmis T, Akinci SB, et al. Magnesium sulfate pretreatment reduces myoclonus after etomidate. Anesth Analg 2005; 101:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. Gastrointest Endosc Clin N Am 2004; 14:247.
          </a>
         </li>
         <li class="breakAll">
          Muse DA. Conscious and deep sedation. In: The Clinical Practice of Emergency Medicine, 3rd ed, Harwood-Nuss, A, Wolfson, AB (Eds), Lippincott, Williams and Wilkins, Philadelphia 2001. p.1761.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2014; 63:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kisilewicz M, Rosenberg H, Vaillancourt C. Remifentanil for procedural sedation: a systematic review of the literature. Emerg Med J 2017; 34:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips WJ, Halpin J, Jones J, McKenzie K. Remifentanil for procedural sedation in the emergency department. Ann Emerg Med 2009; 53:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn MJ, Mitchell R, Souza CD, Drummond G. Evaluation of propofol and remifentanil for intravenous sedation for reducing shoulder dislocations in the emergency department. Emerg Med J 2006; 23:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Gray R, Delavari P, et al. Alfentanil for procedural sedation in the emergency department. Ann Emerg Med 2011; 57:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitetti RD, Singh S, Pierce MC. Safe and efficacious use of procedural sedation and analgesia by nonanesthesiologists in a pediatric emergency department. Arch Pediatr Adolesc Med 2003; 157:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell SG, Magee KD, Kovacs GJ, et al. Procedural sedation and analgesia in a Canadian adult tertiary care emergency department: a case series. CJEM 2006; 8:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ab-Rahman NH, Hashim A. A randomized controlled trial on procedural sedation among adult patients in emergency departments: comparing fentanyl with midazolam versus fentanyl with propofol [abstract]. Ann Emerg Med 2008; 51:479.
          </a>
         </li>
         <li class="breakAll">
          Johnston MN, Liebelt EL. Acute pain management and procedural sedation in children. In: Emergency Medicine: A Comprehensive Study Guide, 6th Ed, Tintinalli, JE, Kelen, GD, Stapczynski, JS (Eds), McGraw-Hill, New York 2004. p.858.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bautista A, Liu R, OngSio LC, Wadhwa A. Pharmacotherapy of procedural sedation in morbidly obese. J Clin Res Pain Anesth 2020; 2:180018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med 2008; 26:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton A, Fitton L. Intravenous ketamine for adult procedural sedation in the emergency department: a prospective cohort study. Emerg Med J 2008; 25:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011; 57:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Michna E, DiNardo JA, et al. Evolution of a protocol for ketamine-induced sedation as an alternative to general anesthesia for interventional radiologic procedures in pediatric patients. Radiology 2002; 225:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chudnofsky CR, Weber JE, Stoyanoff PJ, et al. A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients. Acad Emerg Med 2000; 7:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vardy JM, Dignon N, Mukherjee N, et al. Audit of the safety and effectiveness of ketamine for procedural sedation in the emergency department. Emerg Med J 2008; 25:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sener S, Eken C, Schultz CH, et al. Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. Ann Emerg Med 2011; 57:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhlaghi N, Payandemehr P, Yaseri M, et al. Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial. Ann Emerg Med 2019; 73:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Kuppermann N, Rothrock SG, et al. Predictors of adverse events with intramuscular ketamine sedation in children. Ann Emerg Med 2000; 35:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Clem KJ, Rothrock SG. Ketamine safety profile in the developing world: survey of practitioners. Acad Emerg Med 1996; 3:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortero RF, Clark LD, Tolan MM, et al. The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain. Anesth Analg 2001; 92:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           David H, Shipp J. A randomized controlled trial of ketamine/propofol versus propofol alone for emergency department procedural sedation. Ann Emerg Med 2011; 57:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messenger DW, Murray HE, Dungey PE, et al. Subdissociative-dose ketamine versus fentanyl for analgesia during propofol procedural sedation: a randomized clinical trial. Acad Emerg Med 2008; 15:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willman EV, Andolfatto G. A prospective evaluation of "ketofol" (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. Ann Emerg Med 2007; 49:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loh G, Dalen D. Low-dose ketamine in addition to propofol for procedural sedation and analgesia in the emergency department. Ann Pharmacother 2007; 41:485.
          </a>
         </li>
         <li class="breakAll">
          Aurora, S. Combining ketamine and propofol ("ketofol") for emergency department procedural sedation and analgesia: a review. West J Emerg Med 2008; 9: Article 5 repositories.cdlib.org/uciem/westjem/vol9/iss1/art5 (Accessed on June 17, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips W, Anderson A, Rosengreen M, et al. Propofol versus propofol/ketamine for brief painful procedures in the emergency department: clinical and bispectral index scale comparison. J Pain Palliat Care Pharmacother 2010; 24:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Moore JC, Austad EJ, et al. Randomized, double-blinded, clinical trial of propofol, 1:1 propofol/ketamine, and 4:1 propofol/ketamine for deep procedural sedation in the emergency department. Ann Emerg Med 2015; 65:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan JW, McLeod SL, Iansavitchene A. Ketamine-Propofol Versus Propofol Alone for Procedural Sedation in the Emergency Department: A Systematic Review and Meta-analysis. Acad Emerg Med 2015; 22:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jalili M, Bahreini M, Doosti-Irani A, et al. Ketamine-propofol combination (ketofol) vs propofol for procedural sedation and analgesia: systematic review and meta-analysis. Am J Emerg Med 2016; 34:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferguson I, Bell A, Treston G, et al. Propofol or Ketofol for Procedural Sedation and Analgesia in Emergency Medicine-The POKER Study: A Randomized Double-Blind Clinical Trial. Ann Emerg Med 2016; 68:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andolfatto G, Abu-Laban RB, Zed PJ, et al. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial. Ann Emerg Med 2012; 59:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur M, Singh PM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res 2011; 5:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000; 4:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu YW, Cortinez LI, Robertson KM, et al. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. Anesthesiology 2004; 101:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall JE, Uhrich TD, Barney JA, et al. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000; 90:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott-Warren VL, Sebastian J. Dexmedetomodine: its use in intensive care medicine and anesthesia. BJA Education 2015; 16:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arcangeli A, D'Alò C, Gaspari R. Dexmedetomidine use in general anaesthesia. Curr Drug Targets 2009; 10:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demiraran Y, Korkut E, Tamer A, et al. The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: A prospective, randomized study. Can J Gastroenterol 2007; 21:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jense RJ, Souter K, Davies J, et al. Dexmedetomidine sedation for laryngeal framework surgery. Ann Otol Rhinol Laryngol 2008; 117:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tosun Z, Akin A, Guler G, et al. Dexmedetomidine-ketamine and propofol-ketamine combinations for anesthesia in spontaneously breathing pediatric patients undergoing cardiac catheterization. J Cardiothorac Vasc Anesth 2006; 20:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobias JD. Dexmedetomidine and ketamine: an effective alternative for procedural sedation? Pediatr Crit Care Med 2012; 13:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmaillian M, Kouhestani S, Azizkhani R, et al. Dexmedetomidine versus propofol: An effective combination with ketamine for adult procedural sedation: A randomized clinical trial. Am J Emerg Med 2023; 73:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhong W, Zhang Y, Zhang MZ, et al. Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. J Clin Pharm Ther 2018; 43:414.
          </a>
         </li>
         <li class="breakAll">
          Tu W, Zhou D, Li Z, et al. Dexmedetomidine pharmacokinetics in morbidly obese patients. American Society of Anesthesiologists (ASA) 2015. http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2015&amp;index=7&amp;absnum=4447.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodenius Å, Maddison KJ, Lawther BK, et al. Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers: A Nonblinded Randomized Crossover Study. Anesthesiology 2019; 131:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Jung D, Salisbury S, et al. Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea. J Clin Anesth 2013; 25:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Gunter J, Donnelly LF, et al. A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children. Anesth Analg 2009; 109:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodenius Å, Ebberyd A, Hårdemark Cedborg A, et al. Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers: A Nonblinded, Randomized Crossover Study. Anesthesiology 2016; 125:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro HM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Paediatr Anaesth 2007; 17:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jalowiecki P, Rudner R, Gonciarz M, et al. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005; 103:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Biros M, Krieg S, et al. Randomized clinical trial of propofol versus methohexital for procedural sedation during fracture and dislocation reduction in the emergency department. Acad Emerg Med 2003; 10:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer J, Beauchamp L, Pavich E. Methohexital for procedural sedation of cardioversions in the emergency department. Am J Emerg Med 2022; 58:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Baerdemaeker L, Mortier E, Struys M. Pharmacokinetics in obese patients. Contin Educ Anaesth Crit Care Pain 2004; 93:645.
          </a>
         </li>
         <li class="breakAll">
          Nicolaou DD. Procedural sedation and analgesia. In: Emergency Medicine: A Comprehensive Study Guide, 6th Ed, Tintinalli, JE, Kelen, GK, Stapczynski, JS (Eds), McGraw-Hill, New York 2004. p.275.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss B, Green SM. Sedation and analgesia for procedures in children. N Engl J Med 2000; 342:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malviya S, Voepel-Lewis T, Tait AR. Adverse events and risk factors associated with the sedation of children by nonanesthesiologists. Anesth Analg 1997; 85:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parekh PJ, Oldfield EC, Seniei M, et al. Driving simulator performance ninety minutes post propofol colonoscopy. Am J Gastroenterol 2015; 110:S957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiuchi A, Nakayama Y, Katsuyama Y, et al. Safety and driving ability following low-dose propofol sedation. Digestion 2008; 78:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riphaus A, Gstettenbauer T, Frenz MB, Wehrmann T. Quality of psychomotor recovery after propofol sedation for routine endoscopy: a randomized and controlled study. Endoscopy 2006; 38:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman DH, Azer MM, Pitetti RD, Singh S. When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations. Ann Emerg Med 2003; 42:627.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139217 Version 11.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16997421" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Randomized clinical trial of etomidate versus propofol for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2787127" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The effects of speed of injection on induction with propofol. A comparison with etomidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17083997" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Research advances in procedural sedation and analgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663030" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Procedural sedation in the acute care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9002587" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Etomidate use during emergency intubation of trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11103724" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Etomidate versus succinylcholine for intubation in an air medical setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30175627" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Etomidate versus propofol sedation for electrical external cardioversion: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284883" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Etomidate versus propofol sedation for complex upper endoscopic procedures: a prospective double-blinded randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31341824" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparison of the Sedation Quality of Etomidate, Propofol, and Midazolam in Combination with Fentanyl During Phacoemulsification Cataract Surgery: A Double-Blind, Randomized, Controlled, Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15671976" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical policy: procedural sedation and analgesia in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15829394" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Procedural sedation and analgesia: a review and new concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365337" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Propofol for emergency department procedural sedation and analgesia: a tale of three centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634603" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Propofol sedation by emergency physicians for elective pediatric outpatient procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634601" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23661404" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Propofol for adult procedural sedation in a UK emergency department: safety profile in 1008 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442250" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Procedural sedation of elderly patients by emergency physicians: a safety analysis of 740 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27553482" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Characteristics of and Predictors for Apnea and Clinical Interventions During Procedural Sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25793176" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Intravenous hypnotic regimens in patients with liver disease; a review article.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22218752" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of the dialysis patient in general intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25788766" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Postoperative pain management in patients with chronic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Perioperative Care for the Patient with Renal or Hepatic Disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16928150" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30732981" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17321006" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical practice advisory: Emergency department procedural sedation with propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673779" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The use of propofol for sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673779" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The use of propofol for sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10211008" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19845550" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Randomized clinical trial of propofol with and without alfentanil for deep procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28272252" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparative evaluation of the effect of remifentanil and 2 different doses of esmolol on pain during propofol injection: A double-blind, randomized clinical consort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28212628" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Is propofol injection pain really important to patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21406529" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prevention of pain on injection of propofol: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436859" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24595146" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intravenous lidocaine pretreatment with venous occlusion for reducing microemulsion propofol induced pain: comparison of three doses of lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922881" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A comparison of pretreatment with fentanyl and lidocaine preceded by venous occlusion for reducing pain on injection of propofol: a prospective, randomized, double-blind, placebo-controlled study in adult Japanese surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23198034" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Single pretreatment of remifentanil may reduce pain after propofol and rocuronium injection in rapid sequence induction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22096278" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Role of hydrocortisone in prevention of pain on propofol injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27942060" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Efficacy of methylprednisolone and lignocaine on propofol injection pain: A randomised, double-blind, prospective study in adult cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23956857" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The effect of intravenous dexamethasone and lidocaine on propofol-induced vascular pain: a randomized double-blinded placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28260943" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Efficacy of ondansetron for the prevention of propofol injection pain: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18044291" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Painless injection of propofol: pretreatment with ketamine vs thiopental, meperidine, and lidocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31185906" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Premedication with oral paracetamol for reduction of propofol injection pain: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12190806" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effect of pretreatment with ketorolac on propofol injection pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23588865" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pretreatment with a very low dose of intravenous esmolol reduces propofol injection pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23695645" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Propofol for procedural sedation in the emergency department: a qualitative systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26222247" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The use of propofol for procedural sedation in emergency departments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12907328" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Nurse-administered propofol sedation without anesthesia specialists in 9152 endoscopic cases in an ambulatory surgery center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16761209" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Efficacy and safety of nurse-administered propofol sedation during emergency upper endoscopy for gastrointestinal bleeding: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16285939" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29933097" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Safety and Effectiveness of Nurse-Administered Propofol Sedation in Outpatients Undergoing Gastrointestinal Endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20029168" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Nurse-administered propofol sedation: feasibility and safety in bronchoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33309879" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safety of endoscopist-directed nurse-administered balanced propofol sedation in patients with severe systemic disease (ASA class III).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22050137" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nurse-administered propofol sedation for gastrointestinal endoscopic procedures: first Nordic results from implementation of a structured training program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35295939" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Procedural Sedation Practice: A Review of Current Nursing Standards.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18295374" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Barriers to propofol use in emergency medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17712877" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : "Poachers and dabblers?": ASA president's incautious comment riles emergency physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16863388" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The great debate on nurse-administered propofol sedation (NAPS)--where should we stand?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15173551" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Etomidate for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946280" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Procedural sedation in the community emergency department: initial results of the ProSCED registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12013357" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Etomidate for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34060021" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Etomidate and its Analogs: A Review of Pharmacokinetics and Pharmacodynamics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23525377" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Anesthetic Pharmacology and the Morbidly Obese Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32513237" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915320" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Reducing myoclonus after etomidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12399793" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Etomidate and midazolam for reduction of anterior shoulder dislocation: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136141" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Intravenous etomidate for procedural sedation in emergency department patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17959958" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16115978" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Magnesium sulfate pretreatment reduces myoclonus after etomidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10460557" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Adrenocortical function in critically ill patients 24 h after a single dose of etomidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136139" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Adrenocortical dysfunction following etomidate induction in emergency department patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121142" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pharmacology and pharmacokinetics of sedatives and analgesics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121142" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pharmacology and pharmacokinetics of sedatives and analgesics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24438649" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clinical policy: procedural sedation and analgesia in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28249938" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Remifentanil for procedural sedation: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19111204" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Remifentanil for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16373806" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Evaluation of propofol and remifentanil for intravenous sedation for reducing shoulder dislocations in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16517277" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Procedural sedation and analgesia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947206" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Alfentanil for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14609900" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Safe and efficacious use of procedural sedation and analgesia by nonanesthesiologists in a pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17175868" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Procedural sedation and analgesia in a Canadian adult tertiary care emergency department: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A randomized controlled trial on procedural sedation among adult patients in emergency departments: comparing fentanyl with midazolam versus fentanyl with propofol [abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A randomized controlled trial on procedural sedation among adult patients in emergency departments: comparing fentanyl with midazolam versus fentanyl with propofol [abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8526975" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9272481" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pharmacotherapy of procedural sedation in morbidly obese
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19091264" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Adverse events associated with ketamine for procedural sedation in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18660398" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Intravenous ketamine for adult procedural sedation in the emergency department: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21256625" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12409580" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Evolution of a protocol for ketamine-induced sedation as an alternative to general anesthesia for interventional radiologic procedures in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10730829" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A combination of midazolam and ketamine for procedural sedation and analgesia in adult emergency department patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18723707" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Audit of the safety and effectiveness of ketamine for procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20970888" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30611640" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Premedication With Midazolam or Haloperidol to Prevent Recovery Agitation in Adults Undergoing Procedural Sedation With Ketamine: A Randomized Double-Blind Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10613938" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Predictors of adverse events with intramuscular ketamine sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8727631" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Ketamine safety profile in the developing world: survey of practitioners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11375826" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The effects of small-dose ketamine on propofol sedation: respiration, postoperative mood, perception, cognition, and pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21256626" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A randomized controlled trial of ketamine/propofol versus propofol alone for emergency department procedural sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18754820" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Subdissociative-dose ketamine versus fentanyl for analgesia during propofol procedural sedation: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17059854" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A prospective evaluation of "ketofol" (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341533" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Low-dose ketamine in addition to propofol for procedural sedation and analgesia in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17341533" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Low-dose ketamine in addition to propofol for procedural sedation and analgesia in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21133742" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Propofol versus propofol/ketamine for brief painful procedures in the emergency department: clinical and bispectral index scale comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25441247" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Randomized, double-blinded, clinical trial of propofol, 1:1 propofol/ketamine, and 4:1 propofol/ketamine for deep procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26292077" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Ketamine-Propofol Versus Propofol Alone for Procedural Sedation in the Emergency Department: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26809929" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Ketamine-propofol combination (ketofol) vs propofol for procedural sedation and analgesia: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27460905" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Propofol or Ketofol for Procedural Sedation and Analgesia in Emergency Medicine-The POKER Study: A Randomized Double-Blind Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22401952" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25885374" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Current role of dexmedetomidine in clinical anesthesia and intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11056756" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505441" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702460" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910487" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The effects of increasing plasma concentrations of dexmedetomidine in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Dexmedetomodine: its use in intensive care medicine and anesthesia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19702517" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Dexmedetomidine use in general anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17225879" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: A prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18834067" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Dexmedetomidine sedation for laryngeal framework surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16884981" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Dexmedetomidine-ketamine and propofol-ketamine combinations for anesthesia in spontaneously breathing pediatric patients undergoing cardiac catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22067985" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dexmedetomidine and ketamine: an effective alternative for procedural sedation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37639920" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Dexmedetomidine versus propofol: An effective combination with ketamine for adult procedural sedation: A randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29247451" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29247451" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31403974" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers: A Nonblinded Randomized Crossover Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24096043" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19690241" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27483127" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers: A Nonblinded, Randomized Crossover Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17238880" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16052108" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12957974" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Randomized clinical trial of propofol versus methohexital for procedural sedation during fracture and dislocation reduction in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636047" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Methohexital for procedural sedation of cardioversions in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Pharmacokinetics in obese patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Pharmacokinetics in obese patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738053" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Sedation and analgesia for procedures in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9390581" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Adverse events and risk factors associated with the sedation of children by nonanesthesiologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699144" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Driving simulator performance ninety minutes post propofol colonoscopy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092246" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Safety and driving ability following low-dose propofol sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16810592" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Quality of psychomotor recovery after propofol sedation for routine endoscopy: a randomized and controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14581914" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
